No description available.

El presente estudio se desarrolló en la unidad minera las Águilas, la cual pertenece a la empresa CIEMSA. Ante la actual situación que se presenta ocasionada por la pandemia del SARS-CoV2, en este contexto se presentó la oportunidad de implementar un plan de vigilancia, prevención y control de SARS-CoV2 para la reanudación de actividades económicas, cumpliendo con los lineamientos, directivas y demás disposiciones establecidas por el Ministerio de Salud y protocolo sectorial del subsector minero del Ministerio de Energía y Minas para la vigilancia de la salud de los trabajadores con riesgo de exposición de SARS-CoV2 priorizando el cuidado de la vida y salud con riesgo de exposición en el reinicio de la actividades mineras. Aplicando la metodología de un estudio aplicativo porque su interés es la aplicación sobre una realidad circunstancial que tiene un alcance descriptivo que comprende la descripción de registro, análisis e interpretación de la naturaleza actual de los datos. Con la implementación de plan de vigilancia y protocolos durante el periodo de tiempo, obteniendo como resultado de un 96% del cumplimiento de la implementación y ejecución a las disposiciones establecidas normas nacionales estipulados así mismo se logra el reinicio de actividades con cero contagios y casos positivos en la Unidad Minera las Águilas.

No description available.

<p dir="ltr">The emergence of infectious diseases like HIV, influenza, and COVID-19 highlights the urgent need for highly scalable testing methods that can be deployed outside traditional laboratory settings. Despite decades of research in point-of-care (POC) diagnostics, the main challenge remains the limited performance of assays, especially in terms of sensitivity. Furthermore, most POC assays originating from academic research struggle to transition beyond the laboratory due to manufacturability issues. This dissertation aims to enhance the effectiveness of viral molecular detection platforms for POC diagnostics by improving analytical and clinical sensitivity and facilitating the practical adaptation of academic-developed POC devices for use outside laboratory settings.</p><p dir="ltr">Each aim addresses a separate aspect of device development. The first aim addresses the need for clinical accuracy during test interpretation, especially in POC or at-home diagnostic tests, by developing an internal amplification control (IAC). Here, I develop a one-pot duplex reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assay for detecting SARS-CoV- 2 along that incorporates a housekeeping gene as an IAC to ensure the quality of collected samples and the validity of assay reagents. The valid results can be easily visualized in triple-line lateral flow immunoassay (LFIA). The second aim makes progress towards overcoming the limited analytical sensitivity of existing rapid diagnostic tests for acute HIV infection screening. Here, I introduce a novel antibody-initiated LAMP assay targeting the HIV p24 capsid protein that combines LAMP sensitivity with the specificity of HIV p24 and its antibody. There are 3000 p24 capsid proteins present in the virion compared to only 2 viral RNA copies. In the assay, two DNA- conjugated antibody probes will each bind to p24 and their proximity will allow the DNA overlaps to generate a complete DNA target that acts as a trigger for the LAMP reaction. An LFIA is integrated into this design to enable simple result visualization. The third aim improves manufacturability and assembly of our existing nucleic acid detection platform by simplifying the platform components while maintaining the user-friendly sample-to-answer concept. Here, I validate material compatibility testing, assess chamber fabrication methods amenable to large-scale manufacturing, evaluate alternative heating units, and examine fluid flow control mechanisms of the redesigned wax valve. These combined aims demonstrate promising outcomes for practical implementation of molecular diagnostics to the POC.</p>

Introduktion: Coronavirus är RNA-virus med ett lipidhölje som är täckt utav karaktäristiska spikprotein. De mest kända coronavirusvarianterna är SARS-CoV-1 som var aktiv mellan 2002-2004, MERS-CoV som har varit aktiv sedan 2012 och SARS-CoV-2 som har varit aktiv sedan 2019–tillsvidare. SARS-CoV-2 infektionen betecknades januari 30 2020 som en pandemi. Flera läkemedelsföretag har forcerat ??? till att framställa vaccin riktad mot SARS-CoV-2, “The United States Food and Drug Administration” (FDA) och “European Medicines Agency” (EMA) har nödgats att ge ut “Emergency Use Authorization (EUA) i hopp om att få kontroll på dess spridining. Syfte och mål: Syftet med arbetet är att undersöka säkerheten och effektiviteten hos de EMA-godkända vaccinerna riktade mot SARS-CoV-2. Metod: Studierna för vardera vaccin hittades och valdes ut genom World Health Organizations (WHO) “Draft landscape and tracker of COVID-19 candidate vaccines”. Totalt inkluderades åtta studier baserade på tio kliniska prövningar som undersökte säkerheten och effektiviteten hos de fyra ledande vaccinerna från Pfizer BioNTech, Moderna, AstraZeneca och Johnson &amp; Johnson. Resultat: De fyra undersökta vaccinerna visade en god säkerhet utan grövre biverkningar. De vanligaste biverkningarna hos samtliga vaccin var lokal smärta, trötthet och huvudverk. Dessa biverkningar varade mellan en till två dagar efter vaccination och var till större del milda. Större skillnader kunde ses hos de olika vaccinernas effektivitet, Pfizer BioNTech och Modernas mRNA-vacciner visade på effektiviteter runt 95% medan AstraZeneca och Johnson &amp; Johnsons adenovirus-vektor-vacciner visade på effektiviteter runt 66-70%. Diskussion: Inga större skillnader i säkerhet kunde ses mellan de undersökta vaccinerna. AstraZeneca använde ett influensa vaccin istället för isoton vattenlösning till deras kontrollgrupper. Detta kan ha haft en påverkan på placebo och resultaten från deras prövningar. En tydlig skillnad i effektivitet kunde ses mellan de olika vaccintyperna, vilket har ett stort inflytande på hur lätt man kan inducera flockimmunitet hos en befolkning. Eftersom flockimmunitet har en stor roll i både att bromsa spridningen men även i att förebygga förekomsten av nya virus varianter så bör endast mRNA vacciner rekomenderas om möjligt. / Introduction: Coronaviruses are RNA viruses with a lipid envelope that is covered by characteristic spike protein. The most well-known coronaviruses are SARS-CoV-1 which were active between 2002-2004, MERS-CoV which is active since 2012 and SARS-CoV-2 which is active since 2019. SARS-CoV-2 was designated a pandemic January 30, 2020. Several pharmaceutical companies have been rushing to produce vaccines targeting SARS-CoV-2, The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have had to issue Emergency Use Authorization (EUA) in the hope of gaining control of its spread. Objective: The purpose of this study is to investigate the safety and efficacy of the EMA-approved vaccines targeting SARS-CoV-2. Method: The studies for each vaccine were found and selected through the World Health Organizations' (WHO) "Draft landscape and tracker of COVID-19 candidate vaccines". A total of eight studies were included based on ten clinical trials examining the safety and efficacy of the four leading vaccines from Pfizer BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson. Results: The four vaccines examined showed good safety without any serious side effects, the most common side effects with all vaccines were local pain, fatigue, and headache. These side effects lasted between one to two days after vaccination and were mostly mild. Larger differences could be seen in the efficacy of the different vaccines, with Pfizer BioNTech and Moderna's mRNA vaccines showing efficacies of around 95%. While AstraZeneca and Johnson &amp; Johnson's adenovirus vector vaccines showed efficacies of around 66-70%. Discussion: No major differences in safety could be seen between the vaccines examined. AstraZeneca used an influenza vaccine instead of isotonic aqueous solution for their control groups, this may have had an impact on placebo and thus the results of their trials. A clear difference in efficacy could be seen between the different types of vaccines. This has a great influence on how easily one could induce herd immunity to a population. Herd immunity plays a major role in both slowing the spread but also in preventing the occurrence of new virus variants, therefore mRNA vaccines should be recommended if possible.